Search Results 1771-1780 of 19992 for Receptor
Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-. Cancer. Researchers seek to improve success of chimeric antigen ...
The impact of adjuvant endocrine therapy (AET) omission in estrogen receptor (ER)-low (1%-10%) early-stage breast cancer · Final results of a phase 2 study of ...
denosumab, estrogen therapy or treatment with a selective estrogen receptor modulator, or teriparatide (within the past year). Any history of fracture prior ...
The purpose of this study is tol compare the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual ...
... Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks to based on ...
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting ...
* Diagnosis of anti- phospholipase A2 receptor (PLA2R) negative membranous nephropathy (MN) or anti-PLA2R positive MN but Screening serum anti-PLA2R < 50 RU ...
Dual targeting of aurora-A and progesterone receptor (PR) driven signaling pathways to enhance the therapeutic efficacy of CDK4/6 inhibitors in endocrine ...
... receptor-1/Programmed Death receptor Ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: Participants with locally advanced unresectable or metastatic/recurrent ...
However, Ritting and the research team were surprised to see that this patient's fallopian tube cells did not have any progesterone receptor proteins, which ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.